Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2019-06, Vol.59 (6), p.856-862
Hauptverfasser:	Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Anderson, Jaclyn, Marbury, Thomas C., Othman, Ahmed A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmune diseases Enzyme inhibitors Excretion Exposure Glomerular filtration rate Impairment Janus kinase Janus kinase inhibitor Medical treatment Pharmacokinetics Plasma Regression analysis Renal function renal impairment Rheumatoid arthritis Special Populations upadacitinib Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!